/ Active, not recruiting临床1期 A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.
100 项与 MICA x MICB x Top I 相关的临床结果
100 项与 MICA x MICB x Top I 相关的转化医学
0 项与 MICA x MICB x Top I 相关的专利(医药)